Table 1.
Descriptive characteristics of the study participants
| Characteristics | Summary statistic | |
|---|---|---|
| Enrolment per Calendar year, n (%) | ||
| 2012 | 33 (14.7) | |
| 2013 | 65 (28.9) | |
| 2014 | 72 (32.0) | |
| 2015 | 55 (24.4) | |
| Age in years, median (IQR) | 33 (27–43) | |
| Gender, n (%) | ||
| Female | 145 (64.4) | |
| Male | 80 (35.6) | |
| Duration between HIV diagnosis and enrolment in months, median (IQR) | 6 (2–20) | |
| Time before presentation in months, median (IQR) | 12 (6–24) | |
| History of KS treatment, n (%) | 24 (10.7) | |
| CD4 count in cells/μl, median (IQR) | 231 (137–402) | |
| Skin lesions, n (%) | ||
| Oedema | 74 (32.8) | |
| > 20 lesions | 75 (33.3) | |
| Raised lesions | 125 (55.6) | |
| Skin thickening | 122 (54.2) | |
| Oral lesions, n (%) | 85 (37.8) | |
| Lymphadenopathy, n (%) | 8 (3.6) | |
| Visceral lesions, n (%) | 3 (1.3) | |
| Tumour stage T1, n (%) | 186 (82.7) | |
| Baseline haemoglobin level in g/dl, median (IQR) | 10.7 (10–12) | |
| Baseline creatininaemia in μmol/l, median (IQR) | 77.9 (67.7–89.0) | |
| Antiretroviral therapy regimen, n (%) | ||
| AZT-based | 56 (24.9) | |
| D4T-based | 7 (3.1) | |
| TDF-based | 142 (63.1) | |
| Duration on ART in months, median (IQR) | 6 (0–14) | |
| Chemotherapy cycles, median (IQR) | 8 (2–12) | |
| Severe adverse effects, n (%) | 9 (4.0) | |
| Poor adherence to chemotherapy, n (%) | 19 (8.4) | |
| Treatment response, n (%) | ||
| Complete remission | 65 (28.9) | |
| Partial remission | 53 (23.5) | |
| Stable disease | 15 (6.7) | |
| Unknown response | 92 (40.9) | |
| Outcome, n (%) | ||
| Remain in care | 105 (46.7) | |
| Lost to follow-up | 92 (40.9) | |
| Dead | 28 (12.4) | |